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The Journal of Immunology
Activation of Human gd T Cells by Cytosolic Interactions of
BTN3A1 with Soluble Phosphoantigens and the Cytoskeletal
Adaptor Periplakin
David A. Rhodes,* Hung-Chang Chen,†,1 Amanda J. Price,‡,1 Anthony H. Keeble,‡
Martin S. Davey,†,2 Leo C. James,‡,3 Matthias Eberl,†,3 and John Trowsdale*,3
The three butyrophilin BTN3A molecules, BTN3A1, BTN3A2, and BTN3A3, are members of the B7/butyrophilin-like group of Ig
superfamily receptors, which modulate the function of T cells. BTN3A1 controls activation of human Vg9/Vd2 T cells by direct or
indirect presentation of self and nonself phosphoantigens (pAg). We show that the microbial metabolite (E)-4-hydroxy-3-methyl-
but-2-enyl pyrophosphate binds to the intracellular B30.2 domain of BTN3A1 with an affinity of 1.1 mM, whereas the endogenous
pAg isopentenyl pyrophosphate binds with an affinity of 627 mM. Coculture experiments using knockdown cell lines showed that
in addition to BTN3A1, BTN3A2 and BTN3A3 transmit activation signals to human gd T cells in response to (E)-4-hydroxy-
3-methyl-but-2-enyl pyrophosphate and the aminobisphosphonate drug zoledronate that causes intracellular accumulation of
isopentenyl pyrophosphate. The plakin family member periplakin, identified in yeast two-hybrid assays, interacted with a mem-
brane-proximal di-leucine motif, located proximal to the B30.2 domain in the BTN3A1 cytoplasmic tail. Periplakin did not
interact with BTN3A2 or BTN3A3, which do not contain the di-leucine motif. Re-expression into a BTN3A1 knockdown line
of wild-type BTN3A1, but not of a variant lacking the periplakin binding motif, BTN3A1Dexon5, restored gd T cell responses,
demonstrating a functional role for periplakin interaction. These data, together with the widespread expression in epithelial cells,
tumor tissues, and macrophages detected using BTN3A antiserum, are consistent with complex functions for BTN3A molecules in
tissue immune surveillance and infection, linking the cell cytoskeleton to gd T cell activation by indirectly presenting pAg to the
Vg9/Vd2 TCR. The Journal of Immunology, 2015, 194: 2390–2398.
M
ajor insights into the biology of gd T cells, a pop-
ulation of unconventional or innate T cells character-
ized by their distinct TCR, have been made, linking
their regulation to butyrophilin (BTN)-like molecules (1, 2). Work
in mice has shown that a BTN-like molecule called Skint1 drives
the selection and organ-specific homing of Vg5/Vd1 T cells as-
sociated with the murine skin (3). More recently, the activation of
human Vg9/Vd2 T cells has been linked to BTN3A1. Vg9/Vd2
T cells respond specifically to phosphoantigens (pAg), the mi-
crobial isoprenoid precursor (E)-4-hydroxy-3-methyl-but-2-enyl
pyrophosphate (HMB-PP), shared by many Gram-negative and
Gram-positive bacteria as well as malaria parasites, and at much
higher concentrations, to the related metabolite isopentenyl py-
rophosphate (IPP), which is present in all living prokaryotic and
eukaryotic cells (4, 5). Published reports show that BTN3A1 acts
as an Ag presentation molecule for HMB-PP and IPP (6–8), but
the mechanism remains poorly understood.
BTN3A1 has the structure of a type I receptor of the Ig su-
perfamily and is part of a family of seven BTN receptors encoded
by genes in the MHC (9). BTN molecules are composed of two Ig
domains (IgV, IgC2), a single transmembrane domain, and a large
carboxyl-terminal domain termed B30.2 (or PRYSPRY) located in
the cell cytoplasm. There are three human BTN3A loci, BTN3A1,
BTN3A2, and BTN3A3, and clear orthologs of BTN3A molecules,
now called CD277, are absent from the mouse genome. Despite its
similarity to B7 molecules, BTN3A1 was proposed to act not as
a coreceptor or costimulatory molecule, but rather to directly pre-
sent pAg to the gd TCR in a manner analogous to MHC-restricted
peptide presentation (8). However, this model of BTN3A1 function
has been challenged by conflicting data, which show pAg binding to
a positively charged pocket in the cytosolic B30.2 domain, and that
BTN3A1 does not directly engage the gd TCR (7, 10). This con-
tradictory picture has emerged as a result of the complexity of the
system and in particular by the use of endogenous and exogenous
routes of Ag delivery in in vitro assays. Although the identification
of BTN3A1 as an essential component in the control of human
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Vg9/Vd2 T cells has provided an important insight into the regu-
lation of this T cell subset, clarification of where pAg binds, the role
of the three BTN3A isoforms, and identification of BTN3A1
interacting molecules is required to resolve the molecular basis of
the response.
Materials and Methods
Expression constructs
Primer sequences are listed in Supplemental Table I. BTN expression
constructs were produced using pFLAG vector. For yeast two-hybrid bait
and GST fusions, BTN3A cytosolic tails were cloned into pGBKT7 and
subcloned into pGEX4T1. Periplakin (PPL) construct PPL B7 was pre-
pared by subcloning the pGADT7 insert into pcDNA3hisC. PPL1-495
hemagglutinin (HA) was from L. Sevilla (Cancer Research UK Cambridge
Institute, Cambridge, U.K.). PPLBamH1 was prepared by subcloning the
1.1-kb BamH1 fragment from clone B7 into pcDNA3hisB. DNA encoding
specific short hairpin RNA (shRNA) directed to BTN3A and periplakin were
cloned into pHR-SIREN/puro (a gift from Dr. Nick Matheson, Cambridge
Institute for Medical Research, Cambridge, U.K.) using BamHI/EcoRI. Vi-
rus particles were produced by cotransfection with gag-pol pCMV8.91 and
VSV-G env pMDG plasmids into 293T cells. Supernatant harvested after
48 h was filtered and used to transduce HeLa cells. Clones were selected by
puromycin (1 mg/ml). Sequences targeted by shRNA were: shBTN3A: 59-
CGTGTATGCAGATGGAAAG-39; shBTN3A1: 59-CGTTGATGTGAAG-
GGTTAC-39; shBTN3A2: 59-CGTCGAAGTGAAGGGTTAT-39; shBTN3A3:
59-GCTGCAACAGAGCAAGAAA-39; shPPL#1: 59-ACCAGAAGAACCT-
GCTAGA-39; shPPL#2: 59-GTGGAAGTCAAAGAGGTGA-39; shPPL#3: 59-
GACTGATCGAAAGGTGTGA-39. BTN3A1 cDNA was cloned into the
pHRsinIRES.GFP lentiviral vector using BamH1/Not1. Internal BamH1 sites
were mutated neutrally to facilitate cloning (Quick Change, Stratagene). The
site targeted by shBTN3A1 was also mutated. Site-directed mutagenesis was
then used to create a series of variants targeting the B30.2 domain (H351R,
W391A), periplakin interaction motif (Dexon5, DLL), and the asparagine-
linked glycan (N115D). A stop codon was introduced in exon 8 to produce
a DB30.2 truncation variant. For re-expression, HeLa shBTN3A1 cells were
cotransduced with lentivirus-carrying variant BTN3A1 sequences. GFP+ cells
were sorted using BD FACSAria cell sorter.
Protein expression, purification, and isothermal titration
calorimetry
BTN3A1 residues 310–513 and periplakin residues 133–530 (PPLBamH1)
were expressed with an N-terminal His tag in C41 (DE3) Escherichia coli
cells at 18˚C overnight and purified by capture on Ni-NTA resin (Qiagen)
followed by gel filtration in buffer containing 20 mM TRIS pH 8.0, 150
mM NaCl, 1 mM DTT. Fractions containing pure protein were pooled,
concentrated to 20 mg/ml, and flash-frozen in liquid nitrogen. Isothermal
titration calorimetry (ITC) experiments were conducted on a MicroCal
ITC200. BTN3A1 protein was dialyzed overnight against buffer containing
50 mM TRIS pH 8.0, 150 mMNaCl, and 1 mM DTT. Periplakin protein and
the ligands HMB-PP and IPP (Echelon Bioscience) were dissolved in this
same dialysis buffer. To obtain optimal binding isotherms, we carried out
ITC experiments using the indicated concentrations of BTN3A1 and ligands.
Crystallization, data collection, structure determination, and
refinement
Crystals were grown in 15% PEG 4K, 0.2MMgCl2, Tris pH 8.5. X-ray data
were collected at 100 K on an in-house rotating anode X-ray generator.
Data were processed using MOSFLM and the CCP4 suite. Structure was
determined by molecular replacement using Phaser with 2IWG as a model
(11). Model building was performed using Coot, and refinement was
carried out using REFMAC5. Crystal structure data collection and re-
finement statistics are given (Supplemental Table II). B30.2 structure al-
located accession code 4v1p in Protein Data Bank (http://www.rcsb.org/
pdb/home/home.do).
Ab production
GST fusion proteins were produced in E. coli strain BL21(DE3) grown in
23TY medium at 22˚C and purified using glutathione Sepharose (Amer-
sham). For immunization, bound protein was eluted from washed beads
using reduced glutathione (10 mg/ml in 50 mM Tris-base pH 10.2). Pu-
rified protein (1 mg/ml in 13PBS) was used to immunize rabbits (Cova-
lab). Immune sera (5 ml/45ml 13PBS) were negatively selected twice over
glutathione Sepharose columns preloaded with GST fusion of the recip-
rocal BTN3A B30.2 protein, then immunoaffinity purified. Antisera were
used in immunohistochemistry and immunofluorescence at 10 mg/ml and
immunoblotting at 1 mg/ml.
Immunohistochemistry
Immunohistochemistry in paraffin-embedded tissue microarrays was per-
formed by G. Flack and A. Warford, at the Atlas of Protein Expression
Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus,
Hinxton, Cambridgeshire, U.K., as described previously (12). To establish
whether tissue staining represented true Ab binding, we probed serial
tissue sections with purified rabbit polyclonal preimmune serum. Non-
specific binding of detection reagents was also routinely assessed by
processing tissue sections without primary Ab.
Yeast two-hybrid screen
The Matchmaker GAL4 system (Clontech) was used according to manu-
facturer instructions. All yeast dropout selection media were prepared in-
house (G. Chalkin, Media Kitchen, Cambridge Institute for Medical Re-
search). The bait vector was cotransfected into yeast strain AH109 with
a premade cDNA library of 2 3 106 clones in pGADT7. Selection for two-
hybrid interactions was by growth on quadruple dropout media with color
selection (XaGal). Plasmid DNA from positive interactors were rescued
and inserts were sequenced.
Immunoblot and pull-down assays
Cell lysates were prepared in buffer (50 mM Tris-Cl pH 7.5, 150 mMNaCl,
1% Triton-X, 2 mM PMSF, 5 mM iodoacetamide, EDTA-free protease
inhibitor) by incubation for 10 min at 4˚C, then precleared by centrifu-
gation. For immunoblots (IBs), proteins were solubilized in SDS-PAGE
buffer (5 min, 95˚C) and separated in 10% SDS-PAGE gels, transferred
to Immobilon-P membrane, blocked (5% Marvel/PBS 0.1% Tween 20),
and incubated for 1 h with primary and HRP-conjugated secondary Abs.
Blots were visualized with ECL reagent. Monoclonal M2 anti-FLAG Ab
(Sigma Aldrich) was used. For pull-down assays, cell lysates were incu-
bated at 4˚C with mixing for 2 h with glutathione-Sepharose beads loaded
with GST B30.2 domain fusion proteins. After washing, eluted proteins
were analyzed by IBs and probed with appropriate Ab. Cell fractionation
was carried out using the Qproteome cell compartments kit (Qiagen).
Periplakin antiserum TD2 was from L. Sevilla (Cancer Research UK
Cambridge Institute).
Tissue culture
MCF-7, A431, EJ28 (kind gifts from L. Sevilla), HeLa, 293T, and cos-7 cell
lines were maintained in RPMI 1640 medium plus 10% FCS, penicillin/
streptomycin (100 U/ml), and L-glutamine (2 mM). Cells growing in six-
well plates were transfected with DNA expression constructs using Fugene.
For RT-PCR, Superscript III (Invitrogen) was used to produce first-strand
cDNA from total RNA (200 ng) prepared from cultured cells using RNeasy
(Qiagen). Amplification was carried out using Biomix Taq polymerase
(Bioline). RT-PCR products were analyzed by gel electrophoresis and cloned
using Zero-Blunt Topo (Invitrogen).
T cell assays
Vg9/Vd2 T cells were expanded from healthy donor PBMCs with 1 mM
zoledronate (Zometa; Novartis) and 100 U/ml IL-2 (Proleukin; Chiron) for
14 d. At the end of the culture period, gd T cells were further enriched by
negative selection with a modified human gd T cell isolation kit that
removes B cells, ab T cells, NK cells, dendritic cells, stem cells, gran-
ulocytes, and monocytes (Stem Cell Technologies). All gd T cells used in
this study were.90% CD3+ Vg9+ as determined by FACS analysis. Target
HeLa cells were pulsed overnight with 10 mM zoledronate, washed ex-
tensively, and cocultured with gd T cells at a ratio of 1:1 (2 3 104 cells
each). Alternatively, untreated HeLa cells were cocultured with gd T cells
in the absence or presence of 10 nM HMB-PP (a gift from H. Jomaa,
Giessen, Germany). The amount of IFN-g secreted into the culture su-
pernatant over 24 h was measured by ELISA (eBioscience). Mobilization
of CD107a onto the cell surface over the first 5 h of coculture was de-
termined using a PE-conjugated anti-CD107a Ab (H4A3; BD Biosciences)
in the presence of monensin at a 1:200 dilution (GolgiStop). Cells were
acquired on a FACS Canto II and analyzed with FlowJo.
Results
pAg bind to the BTN3A1 B30.2 domain
The possibility that pAg interact with the B30.2 domain of
BTN3A1 was first proposed by Harly et al. (7). As a result of our
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interest in the B30.2 domain of TRIM21, a high-affinity cytosolic
FcR (11), we favored this hypothesis. The B30.2 domain repre-
sents a credible structure for binding small molecules in the cell
cytoplasm with high affinity. Therefore, we investigated the
structure and binding interactions of the BTN3A1 B30.2 domain
(Fig. 1A, 1B). The crystal structure, like that of the B30.2 domains
of TRIM21 and TRIM5 (13), shows it to be composed of layered
antiparallel b sheets with variable loops, a structure homologous
to the Ig fold. The juxtaposition of B30.2 domain variable loop
residues forms the specific binding interface. The BTN3A1 B30.2
domain structure has also been presented by Sandstrom et al. (10),
who identified a credible pocket implicated in binding pAg ligand,
characterized by a cluster of positively charged residues (Fig. 1B).
In addition to the residues highlighted by Sandstrom et al. (10),
particularly arginine residues at R412, R418, and R469, histidines
H351 and H378 and the single lysine K393, our apo structure
suggests a role in coordinating Ag for tryptophan residues W350
and W391. In particular, the indole of W391 may form a hydrogen
bond with phosphates in the bound ligand (Fig. 1B).
Binding of HMB-PP and IPP to the BTN3A1 B30.2 domain was
investigated by ITC. HMB-PP was found to bind with an affinity of
1.1 mM (Fig. 1C) and IPP with an affinity of 672 mM (Fig. 1D),
values that are similar to those reported (10) and that help explain
the 1000- to 10,000-fold difference in bioactivity of the two
molecules on human gd T cells (5). Therefore, our results extend
the findings of Sandstrom et al. (10) and confirm the intracellular
interactions of pAg to the B30.2 domain.
Identification of periplakin as a BTN3A1 interacting molecule
Next, we set out to explore the significance of the BTN3A1 cy-
toplasmic tail, including the B30.2 domain, by identifying inter-
acting molecules using yeast two-hybrid experiments. The BTN3A1
cytoplasmic tail was cloned into the pGBKT7 bait vector and used to
screen a human cDNA library. Twelve clones showed consistent
yeast two-hybrid interactions. Further validation on dropout media
with color selection against empty bait vector pGBKT7 identified
six BTN3A1-specific two-hybrid interacting clones, which were
sequenced.
Candidate clones were validated using GST pull-down assays.
Inserts in the pGADT7 library vector were subcloned into pcDNA3
to give anti-Xpress fusion constructs, which were transfected into
Cos-7 cells. Cell lysates were incubated with glutathione Sepharose
beads preloaded with B30.2 domain GST fusion proteins. After
washing, bound protein was eluted and analyzed by IB using anti-
Xpress. Clone B7 showed positive interactions by these methods,
representing aa 126–657 of periplakin, a 195-kDa cytosolic pro-
FIGURE 1. Structure of the
BTN3A1 B30.2 domain. (A) Over-
view of the fold is shown with
binding-site residues shown in stick
representation. (B) A close-up view
of the proposed pAg binding site
showing the molecular surface and
important interface residues (10). (C
and D) ITC was used to show bind-
ing of pAg to BTN3A1 B30.2 do-
main. HMB-PP→BTN3A1 at 0.639
mM into HMB-PP at 0.064 mM;
IPP→IPP at 6 mM into BTN3A1 at
0.597 mM.
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tein of the cytoskeleton-associated plakin family (14, 15). Inter-
action was specific to BTN3A1 because periplakin did not interact
with BTN2A1 or BTN3A3 fusion protein in pull-down assays
(Supplemental Fig. 1A).
Immunoprecipitation (IP) was used to confirm the periplakin–
BTN3A1 interaction in vivo (Fig. 2A). Expression constructs FLAG
BTN3A1 and PPL1-495 with HA tag were transfected individually
or together into 293T cells. Anti-HA Ab was used to recover protein
complexes, followed by IB using FLAG Ab. FLAG BTN3A1 was
recovered from cell lysates by IP using HA Ab, only in the presence
of PPL1-495 HA (Fig. 2A, upper panel). The two lower panels of
Fig. 2A show IB of cell lysates to confirm protein input.
ITC experiments were used to investigate the interaction of
BTN3A1 and periplakin proteins in vitro. A binding affinity of 2 mM
was calculated for the BTN3A1 cytoplasmic tail interacting with
a periplakin fragment representing the XYZ a helices of the plakin
domain, with 1:1 stoichiometry (Fig. 2B). Using a series of BTN3A1
deletions produced by site-directed mutagenesis, the periplakin in-
teraction site was localized to aa 305–310, overlapping with exon 5
of the BTN3A1 cDNA sequence (Supplemental Fig. 1B).
An interaction of periplakin with a BTN3A1 splice variant,
3A1v2, which lacks the B30.2 domain (NM_194441), was dem-
onstrated by GST pull-down assay and IP (Supplemental Fig. 1C,
1D). Using ITC, a binding affinity of 0.58 mM was calculated for
the 3A1v2 cytoplasmic tail interaction with periplakin (Supplemental
Fig. 1E), a slightly increased affinity than that found for the full-
length BTN3A1/periplakin interaction. The results showed that per-
iplakin interacted with full-length BTN3A1 (Fig. 2) and a truncated
splice variant BTN3A1v2 (Supplemental Fig. 1), indicating that the
B30.2 domain was not required for binding. Periplakin was also
shown to interact with BTN1A1, the BTN molecule expressed in
human milk (Supplemental Fig. 1D).
Periplakin is a large cytosolic protein of 1756 aa, composed of
six a helices (the plakin domain) and a large coiled-coil rod
FIGURE 2. Interaction of BTN3A1 with periplakin. (A) Interaction of periplakin and BTN3A1 in vivo by IP. 293T cells were transfected with ex-
pression constructs PPL1-495 HA and FLAG BTN3A1 either alone or together. Protein complexes were recovered by IP using anti-HA Ab and analyzed
by IB using anti-FLAG (upper panel) or anti-HA (second panel) Abs. FLAG BTN3A1 was recovered from anti-HA IP only in the presence of PPL1-495
HA. Lower panels show input lysates analyzed by IB. Protein bands with molecular weights lower than the introduced expression constructs were
detected for both BTN3A1 and periplakin in IP experiments, as shown, which likely represents postlysis proteolytic cleavage of proteins. (B) ITC was
used to confirm thermodynamically favorable interaction between purified BTN3A1 and PPL BamH1. Binding affinity in the low-micromolar range (2.1
mM) was calculated. (C) Diagram of domain structure of periplakin (14) showing expression constructs used. Clone B7 represented periplakin aa 126–657
plus 26 additional amino acids, showing similarity to XP_001098863 periplakin-like sequence from Macaca mulatta. (D) Alignment of amino acids
(306–312) encoded by exon 5 of BTN3A1 compared with other BTN proteins. (E) Periplakin interaction via the di-leucine motif in BTN3A1. IP of wild-
type BTN3A1 and variants lacking either exon 5 or the di-leucine motif. 293T cells were transfected with the indicated BTN3A expression constructs
together with PPL1-495 HA. Periplakin and associated proteins were recovered from cell lysates by IP using anti-HA Ab and analyzed by IB using anti-
FLAG. Bottom panels show IB of input lysates using anti-FLAG and anti-HA acting as a loading control.
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domain (Fig. 2C). Clone B7, identified by yeast two-hybrid
assays, represented a splice variant lacking the rod domain but
covering the plakin domain. The minimal binding interfaces
were identified between aa 396–495, containing the central X
region of the plakin domain of periplakin interacting with exon 5
of BTN3A1.
A comparison of the 7 aa encoded by exon 5 from BTN mol-
ecules showed a di-leucine motif in BTN1A1 and BTN3A1, the
only molecules to bind periplakin, not found in BTN2A1, BTN3A2,
or BTN3A3 (Fig. 2D). The interaction of periplakin with full-length
BTN3A1 was compared with constructs carrying deletions of either
the di-leucine or exon 5 (Fig. 2E). Constructs for BTN3A2 and
BTN3A3 were also included. Periplakin interacted with full-length
BTN3A1 alone and not with any of the other constructs. Therefore,
periplakin interacts with the di-leucine motif in the juxtamembrane
domain of BTN3A1, proximal to the B30.2 domain, a sequence
motif also found in BTN1A1.
Expression of BTN3A in human cells and tissues
To assess protein expression from individual BTN3A loci, we
produced Abs to B30.2 domains. BTN3A1 and BTN3A3 B30.2
domains as GST fusion proteins were used for immunization. This
approach could not be used for BTN3A2, which does not have a
B30.2 domain. IB of cell lysates from 293T cells transfected
with FLAG-tagged BTN3A constructs was used to assess anti-
sera specificity (Fig. 3A). Anti-FLAG Ab IB, used as a loading
control, showed that FLAG BTN3A proteins in some cases
formed dimeric complexes at high expression levels. Antiserum
056 was confirmed to be specific for BTN3A1, whereas anti-
serum B6 was predominantly against BTN3A3, with cross-
reactivity with BTN3A1. B6 antiserum showed similar staining
specificity in immunofluorescence microscopy of transfected
293T cells, recognizing predominantly BTN3A3, with cross-
reactivity to BTN3A1 (Fig. 3B).
To determine BTN3A protein expression, we prepared and an-
alyzed detergent lysates from human tumor-derived cell lines by
SDS-PAGE followed by IB using the B6 and 056 antisera. BTN3A1
and BTN3A3 were expressed at low abundance in most lines tested
at the expected molecular masses of 57 and 65 kDa, respectively,
with the two proteins showing identical distribution (Fig. 3C).
A lower molecular mass band of 37 kDa was evident using the
BTN3A1-specific Ab 056, particularly in human breast adenocar-
cinoma MCF-7 cells, indicative of alternative splicing or proteolytic
cleavage of BTN3A1.
HeLa cell lines expressing shRNA vectors targeting BTN3A
transcripts were produced and cell lysates analyzed by IB, to
confirm specificity of antisera (Fig. 3D). The sh3A1 vector was
specific for BTN3A1, because antiserum 056 cross-reacting bands
were depleted in this cell line. The sh3A vector efficiently knocked
down expression of BTN3A3, recognized by B6 antiserum, but
did not affect expression of BTN3A1.
The B6 antiserum gave specific results by IB and immunoflu-
orescence microscopy, indicating that it would be useful in as-
sessing protein expression in tissues. The B6 antiserum was used in
immunohistochemistry against paraffin-embedded human tissue
sections. Widespread epithelial and tissue macrophage cell staining
was detected (Fig. 3E–G and Supplemental Fig. 2). Tumor sec-
tions showed more intense staining than that observed in normal
epithelium, for example, in breast tumor tissue sections (Fig. 3E).
There was notable staining of endocrine tissues including pan-
creatic islets (Fig. 3F). Macrophages in the spleen, liver Kupffer
cells (Supplemental Fig. 2), and lung macrophages (Fig. 3G) also
showed strong staining.
Activation of gd T cells requires multiple BTN3A isoforms
BTN3A1 was previously shown to transmit activation signals to
Vg9/Vd2 T cells in the presence of pAg stimulation (16). To test
the role played by BTN3A1 in activating Vg9/Vd2 T cells, we
used the two HeLa cell lines expressing shRNA vectors targeting
BTN3A molecules characterized in Fig. 3D. Specific knockdown
by these shRNAs was confirmed by RT-PCR (Fig. 4A). In co-
culture experiments, sh3A and sh3A1, together with shRNA
empty vector control (HeLa EV), were pulsed with zoledronate to
induce intracellular accumulation of IPP and incubated overnight
with expanded gd T cells. To test the effect of exogenously pro-
vided pAg, we also cocultured HeLa cells and gd T cells in the
absence or presence of the microbial metabolite HMB-PP. Culture
supernatants were analyzed by ELISA for IFN-g (Fig. 4B, 4C).
These experiments confirmed the critical role played by BTN3A1
in gd T cell activation, but showed additional complexity depen-
dent upon the T cell activation marker and the stimulus used. In
FIGURE 3. BTN3A protein expression in human cells and tissues. (A)
293T cells were transfected with pFLAG BTN expression constructs. Cell
lysates were analyzed by nonreducing SDS-PAGE and IB using anti-FLAG
and rabbit anti-B30.2 domain antisera 056 and B6 and goat anti-rabbit
HRP secondary Abs. BTN3A1v2 is a truncated molecule lacking the B30.2
domain. Protein molecular mass in kDa. (B) Immunofluorescence mi-
croscopy of 293T cells transfected with expression constructs for BTN3A3
and BTN3A1. Fixed and Triton X-100 permeabilized cells (0.1%) were
stained with antiserum B6/goat anti-rabbit Alexa 488 Abs (green) and
carboxyl-terminal V5/goat anti-mouse Alexa 568 (red). Original magnifi-
cation 320. (C) BTN3A protein expression by IB of Triton X-100 deter-
gent cell lysates from human epithelial carcinomas cell lines, as shown,
probed with antisera 056 and B6 and goat anti-rabbit HRP secondary Abs.
Loading control by b-actin Ab. (D) BTN3A expression in HeLa cells se-
lected for expression of BTN3A shRNA knockdown vectors. Cell lysates
were analyzed by IB with antisera 056 and B6 and by b-actin Ab. (E–G)
Immunohistochemistry on human tissue array probed with Ab B6. Original
magnification 320. (E) Breast tumor tissue. (F) Islets of Langerhans. (G)
Macrophages in the lung. Control panels [lower panels in (E)–(G)] were
serial tissue sections stained with preimmune serum.
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addition, although our analysis of protein expression showed that
the sh3A line expressed BTN3A1, but not BTN3A3, whereas the
sh3A1 line expressed BTN3A3, but not BTN3A1 (Fig. 3D), the
data were also consistent with a requirement for multiple BTN3A
isoforms in gd T cell activation.
Because of the apparent discrepancy of these findings with
published reports that excluded a role for BTN3A2 and BTN3A3 in
gd T cell regulation (7), two further knockdown lines, sh3A2 and
sh3A3, which target specifically BTN3A2 and BTN3A3, respec-
tively, were produced. Because anti-BTN3A Ab CD277 stained
HeLa cells poorly, we do not have Abs specific to BTN3A2 and
we could not consistently show presence/absence of protein using
BTN3A antisera; knockdown lines were analyzed by RT-PCR.
cDNA amplification to detect full-length transcripts for each of
the BTN3A isoforms showed that shRNA vectors were specific to
their targeted transcript (Fig. 4A). When tested in gd T cell assays,
the production of IFN-g, induced by either soluble HMB-PP (Fig. 4B)
or in response to zoledronate-pulsed target cells (Fig. 4C), was effi-
ciently blocked in all BTN3A knockdown lines compared with the
vector control line, with only the BTN3A3 line showing a reduced
knockdown phenotype in response to HMB-PP. Taken together, the
results demonstrated a role for all three BTN3A isoforms in regu-
lating pAg-induced gd T cell activation.
Role of periplakin in gd T cell activation
The interaction of BTN3A1 with periplakin (Fig. 2) implied a role
for this cytoskeletal adaptor in the regulation of gd T cell re-
sponses. Because of limitations in the choice of specific Abs and
the fact that both proteins are of low abundance, a direct dem-
onstration of the interaction of endogenous BTN3A1 with peri-
plakin by coimmunoprecipitation has not been possible. In addition,
periplakin is a large protein of 195 kDa associated with cyto-
skeletal structures generally resistant to detergent solubilization.
To detect periplakin consistently, we used cell fractionation
based on detergent solubilization to produce soluble, membrane,
nuclear, and cytoskeletal/detergent resistance membrane protein
fractions (Fig. 5A). Fractions from 2 3 106 HeLa cells were
analyzed by SDS-PAGE and probed with periplakin Ab. A series
of control Abs was used to demonstrate the efficiency of frac-
tionation using this protocol. Periplakin was found to be gen-
erally distributed in cell fractions, but detected most robustly in
the cytoskeletal/detergent-resistant membrane fraction, which
was also positive for flotillin-2, a marker for caveolae or lipid
raft domains (Fig. 5A).
To address the role of the BTN3A1–periplakin interaction on
a functional level, we produced HeLa cell lines expressing shRNA
targeting different regions of periplakin (PPL). Cytoskeletal/
detergent resistance membrane fractions were isolated and ana-
lyzed by IB using antiperiplakin antiserum. All three PPL shRNA
lines showed reduced or absent levels of periplakin (Fig. 5B, left
panel). When analyzed similarly, the sh3A1 knockdown line showed
reduced levels of periplakin, indicating that expression of periplakin
may be linked to BTN3A1, possibly by stabilization of the protein
(Fig. 5B, right panel).
The effect of periplakin on the production of IFN-g by acti-
vated gd T cells was analyzed using the periplakin knockdown
lines in coculture experiments (Fig. 5C). Compared with the vector
control (HeLa EV), two knockdown lines, PPLsh#1 and PPLsh#3,
showed reduced IFN-g production in response to HMB-PP (Fig. 5C,
left panel). The PPLsh#2 line, in contrast, showed an increase in
IFN-g production. In response to IPP accumulation induced by
zoledronate pretreatment (Fig. 5C, right panel), PPLsh#1 reduced
IFN-g production, PPLsh#2 showed no change, and PPLsh#3
showed a slight increase in IFN-g levels. The results, which were
consistent over multiple experiments (n = 5; Fig. 5D), showed
that periplakin knockdown did not consistently block, but caused
dysregulated gd T cell responses to pAg exposure, as assessed by
IFN-g production. There was variation in the response to the dif-
ferent pAg, exogenous HMB-PP and endogenous IPP induced by
zoledronate, by individual PPL knockdown lines that appeared to be
dependent on which part of the periplakin molecule was targeted by
shRNA.
To find clearer evidence of a role for periplakin, we used
transcript re-expression into the sh3A1 cell line, which had been
rendered unresponsive in T cell assays by shRNA-suppressing
endogenous BTN3A1. Re-expression of BTN3A1 was achieved
using the lentivirus system, where expression was monitored using
IRES-driven GFP. A series of BTN3A1 variant lines were pro-
duced, targeting the proposed pAg binding motif in the B30.2
domain (H351R, W391A), the site of periplakin interaction
(Dexon5, DLL), and the asparagine-linked glycan in the Ig IgV
domain (N115D). A DB30.2 domain truncation variant, carrying
a stop codon in exon 8, was used as an additional control.
BTN3A1 protein expression in the reconstituted lines was con-
firmed by IB with anti-BTN3A1 Ab 056. Endogenous BTN3A1
was not detected in the untransfected HeLa line in these experi-
mental conditions (Fig. 6A). IFN-g levels induced by the recon-
stituted lines, in the presence of zoledronate pretreatment (Fig. 6B,
left panel) or HMB-PP in coculture (Fig. 6B, right panel), were
compared with those from empty vector control HeLa EV (posi-
tive) and sh3A1 (negative) parental lines in gd T cell assays. IFN-g
production from T cells was rescued by coculture with wild-type
FIGURE 4. BTN3A-dependent activation of gd T cells. (A) BTN3A knockdown by expression of shRNA targeting each isoform. Full-length BTN3A
transcripts were amplified by RT-PCR from cDNA derived from HeLa BTN3A knockdown cell lines. Amplification of b2microglobulin was used as
a template control. RT-PCR products were analyzed by gel electrophoresis. Size in kb. (B and C) Coculture of gd T cells with BTN3A knockdown lines and
empty vector control (HeLa EV). T cell activation was induced by (B) 10 nM HMB-PP in coculture or (C) pretreatment of HeLa cells with 10 mM
zoledronate. IFN-g secretion into culture medium was detected by ELISA. Data shown are mean values obtained from four independent experiments using
gd T cells from PBMCs of three individual donors, with error bars (SEM). w/o, without pAg.
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BTN3A1 and N115D re-expression, but not by the B30.2 domain
variants H351R and W391A, nor by the Dexon5 and DLL deletions.
The DB30.2 deletion variant was also unable to rescue T cell
responses. In addition, the IFN-g recovery response to HMB-PP
by reconstituted wild-type cells was less efficient than for zole-
dronate. These data therefore provide functional confirmation of
the critical requirement for the B30.2 domain, of key residues
within this domain implicated in pAg binding and for the
BTN3A1 periplakin interaction motif residues, in pAg-dependent
activation of gd T cells, with the likelihood that additional un-
identified factors are required (17).
Discussion
BTN3A1 has been shown to regulate Vg9/Vd2 T cells, a subset of
human T cells that elicit immune responses to microbial infection
and with potent antitumor activity (7, 8, 18). Activation of Vg9/
Vd2 T cells is achieved specifically by presentation of low-m.w.
pAg such as HMB-PP and IPP. Our results address directly the
complex mechanism of pAg sensing by BTN3A1, confirming that
both HMB-PP and IPP bind to the cytosolic BTN3A1 B30.2 do-
main with affinities of 1.1 and 672 mM, respectively, in line with
affinities reported previously (10). What is less clear is how such
binding is transmitted to the gd TCR. BTN3A1 conformational
change, redistribution in the cell membrane as a result of pAg
binding, and recruitment of other molecules required for TCR
engagement are the current proposals (10).
We demonstrate a specific interaction of BTN3A1 with the
cytoskeletal adaptor protein periplakin. Published results indicate
a role for the plakin protein family, including periplakin, in tissue
homeostasis and regulation of immune responses in epithelium
(19). pAg-dependent responses could be restored to a BTN3A1
knockdown cell line by re-expression of wild-type BTN3A1, but
not by variants lacking the periplakin interaction motif, confirm-
ing a critical role for this motif in transmitting activation signals to
gd T cells. Assays in the presence of periplakin knockdown cells
were less conclusive. We detected a block in T cell activation
induced by HMB-PP in only two of the three periplakin knock-
down lines, and responses to zoledronate treatment were also not
blocked completely, with IFN-g levels in some experiments being
increased. Although the binding and re-expression data implicated
periplakin as a component of the pathway controlling gd T cell
activation, the dysregulated responses showed that periplakin has
more of a regulatory role and that other factors may compensate
for its absence by binding the same motif on BTN3A1. Analysis
of the BTN3A1 knockdown cell line using anti-periplakin Ab
showed that periplakin protein was reduced to levels comparable
with that observed using specific periplakin knockdown reagents
(Fig. 5B). Although we could not confirm any effect of periplakin
knockdown on BTN3A1 protein using anti-BTN3A antisera by the
reciprocal experiment, the results indicated that periplakin ex-
FIGURE 5. Role of periplakin in gd T cell activation. (A) Cell frac-
tionation based on detergent solubilization. Fractions from HeLa cells (23
106) were analyzed by SDS-PAGE and IB using antiperiplakin antiserum
TD2. Control Abs were used to show efficiency of fractionation into (1)
cytosolic, (2) membrane, (3) nuclear, and (4) cytoskeletal/detergent-re-
sistant membrane fractions. Anti–b-actin Ab acts as a loading control. (B)
Periplakin knockdown by expression of shRNA in HeLa cells (left panel).
Cytoskeletal/detergent-resistant membrane fractions were prepared and
analyzed by IB using antiperiplakin antiserum. IB of detergent-resistant
fractions in BTN3A and periplakin knockdown cells (right panel). Anti–b-
actin Ab acts a loading control in each case. (C) Coculture of gd T cells
with periplakin shRNA knockdown lines PPLsh#1, PPLsh#2, and
PPLsh#3. T cell activation was induced using 10 nM HMB-PP (left panel)
or 10 mM zoledronate (right panel), and IFN-g secretion into culture
medium was detected by ELISA. HeLa EV empty vector control. Data
shown are representative of five independent experiments, with error bars
(SEM). (D) Analysis of data from (C) of gd T cell stimulation induced
from PPL knockdown cells. Box plots (depicting 25th percentile, median,
75th percentile, and highest/lowest data point whiskers) of relative change
in IFN-g responses compared with vector control (HeLa EV), from n = 5
determinations. Differences between groups were assessed by one-way
ANOVA. A p value,0.05 was considered significant. **p, 0.01, ***p,
0.001. w/o, without pAg.
FIGURE 6. Activation of gd T cells requires the B30.2 domain and
periplakin interaction motif. (A) Analysis of re-expression lines using anti-
BTN3A1 Ab 056. IB analysis of total protein (10 mg) from Triton-X100
detergent lysates from HeLa, HeLa sh3A1 knockdown line, and the pa-
rental sh3A1 cell line transduced additionally with IRES.GFP lentivirus–
expressing wild-type BTN3A1, H351R, W391A, Dexon5, DLL, DB30.2,
and N115D variants. Duplicate IB using b-actin acts as loading control.
Endogenous BTN3A1 protein was not detectable by 056 antiserum in the
untransfected HeLa cell lysate in these experimental conditions. BTN3A1
DB30.2 variant protein was also not detected using the 056 antiserum. (B)
Analysis of re-expression lines in gd T cell assays. Graph shows percent (%)
IFN-g recovery response from each of the re-expression lines compared with
the vector control HeLa EV (positive) and sh3A1 knockdown (negative)
lines. Data produced using gd T cells from six individual donors.
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pression may be dependent on coordinated expression of BTN3A
molecules, adding further complexity to the mechanism. The ge-
nomic organization at the periplakin locus on human chromosome
16p13 could also predispose the molecule to alternative splicing
(20), which may contribute to evasion of shRNA-mediated sup-
pression, variation in expression according to cell type, or in re-
cruitment of known periplakin-interacting proteins envoplakin,
involucrin, or kazrin (21, 22). Our working model is that binding
of pAg to the BTN3A1 B30.2 domain recruits periplakin to in-
crease avidity interactions or synapse formation by, for example,
anchoring or redistribution in the membrane, receptor clustering,
or recruitment of other molecules into a signaling complex. It will
be important to establish whether binding affinity is altered in any
way, and such studies will inform attempts at crystallization of the
periplakin/BTN3A1 or the trimolecular complex with pAg.
Recent nuclear magnetic resonance analyses confirm a confor-
mational change in the B30.2 domain upon pAg binding, extending
to the BTN3A1 membrane-proximal region where periplakin binds
(23). Fluorescence recovery after photobleaching experiments
showed BTN3A1 redistribution and anchoring in pAg-pulsed cells
(10). Given our results, it is also feasible that periplakin–BTN3A1
interaction impacts negatively on gd T cell activation, regulates
uptake of exogenous HMB-PP in an endocytic compartment, or that
gd T cell activation is conveyed by a BTN3A-dependent signaling
mechanism.
The N-terminal plakin domain of periplakin, composed of six
spectrin repeat a-helices and central SH3 domain (24), interacted
with the cytoplasmic tail of BTN3A1 (and BTN1A1) via a mem-
brane-proximal di-leucine motif. Di-leucine is a well-characterized
motif involved in sorting and endocytosis in the secretory pathway,
controlling protein localization and trafficking. Canonical di-
leucine motifs have an upstream acidic residue, positioned at -4
(D/ExxxLL) or -3 (DxxLL/LI), where x is any amino acid, and
bind either the AP2 clathrin adaptor or GGAs, respectively (25,
26). In contrast, the BTN3A1 sequence (TMKQEQSTRVKL-
LEEL) has an acidic residue at position -7, suggesting a molecular
mechanism with characteristics of E-cadherin–p120-catenin path-
ways (27). Masking of the endocytic di-leucine motif by p120
stabilizes E-cadherin expression at the cell surface (28). Consistent
with our model, periplakin recruitment to the BTN3A1 di-leucine
motif may be required for T cell activation by acting similarly, to
enhance stability of the BTN3A1–pAg complex.
BTN3A knockdown lines, produced in HeLa cells by stable
expression of shRNA vectors, were used in coculture experiments
with gd T cells and activation markers analyzed. The results con-
firmed the critical role played by BTN3A1 in activation of gd
T cells by pAg stimulation, and in addition showed that BTN3A2
and BTN3A3 are also required. The BTN3A isoform knockdowns
showed responses, particularly with regard to IFN-g production
(Fig. 4), which were in most cases comparable with BTN3A1
knockdown in our assays. These data appear to be a discrepancy
between other published reports, which have excluded a role for
BTN3A2 and BTN3A3. The pAg binding pocket residues iden-
tified in the B30.2 domain of BTN3A1 (10), including the tryp-
tophan residues at W350 and W391 (Fig. 1B), are conserved in
BTN3A3, suggesting that BTN3A3 may bind pAg. This possi-
bility has been excluded (10) and we have confirmed that the
BTN3A1 H351R variant is nonfunctional in T cell assays. In ad-
dition, BTN3A2 does not contain a B30.2 domain, and neither
BTN3A2 nor BTN3A3 bind periplakin. However, the BTN3A
isoforms show .95% amino acid identity across Ig domains, so it
may be that BTN3A2 and BTN3A3 act more as chaperones to
modulate BTN3A1 trafficking or in protein complex formation,
requiring coordinated expression.
Our data are consistent with the model of BTN3A1 regulation of
gd T cells, for which there is considerable evidence (7, 10, 18, 23),
that pAg binding is presented indirectly to the gd TCR, and are
not consistent with the direct binding model presented by
Vavassori et al. (8). We have confirmed that HMB-PP, and with
lower-affinity IPP, bind to the BTN3A1 B30.2 domain. Our refined
model proposes that transmission of pAg binding from the cytosol
to the gd TCR requires, in addition to BTN3A1, the isoforms
BTN3A2 and BTN3A3, recruitment of periplakin, and possibly
other members of the plakin family of cytolinker proteins, which
serve to anchor or stabilize a BTN3A signaling complex in the cell
membrane. In this scenario, the cytosolic sensing of metabolic
intermediates of the endogenous mevalonate and pathogen-
specific nonmevalonate pathways by BTN3A molecules may not
require that pAg access the lumen of the endoplasmic reticulum,
as for canonical MHC-I Ag presentation.
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